nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR1—malignant glioma	0.273	0.422	CbGaD
Ponatinib—PDGFRA—malignant glioma	0.21	0.325	CbGaD
Ponatinib—KDR—malignant glioma	0.163	0.253	CbGaD
Ponatinib—Effusion—Carmustine—malignant glioma	0.00715	0.0916	CcSEcCtD
Ponatinib—FGFR3—skull—malignant glioma	0.00562	0.0714	CbGeAlD
Ponatinib—Ocular toxicity—Carmustine—malignant glioma	0.00554	0.071	CcSEcCtD
Ponatinib—FGFR2—skull—malignant glioma	0.00368	0.0467	CbGeAlD
Ponatinib—KDR—umbilical vein—malignant glioma	0.00273	0.0347	CbGeAlD
Ponatinib—Cerebral infarction—Carmustine—malignant glioma	0.0023	0.0295	CcSEcCtD
Ponatinib—FGFR4—embryo—malignant glioma	0.00203	0.0258	CbGeAlD
Ponatinib—FGFR4—brainstem—malignant glioma	0.00186	0.0237	CbGeAlD
Ponatinib—Myelosuppression—Carmustine—malignant glioma	0.0016	0.0205	CcSEcCtD
Ponatinib—TEK—endothelium—malignant glioma	0.00158	0.0201	CbGeAlD
Ponatinib—Myelosuppression—Temozolomide—malignant glioma	0.00155	0.0198	CcSEcCtD
Ponatinib—TEK—blood vessel—malignant glioma	0.00146	0.0185	CbGeAlD
Ponatinib—Lymphopenia—Temozolomide—malignant glioma	0.00142	0.0181	CcSEcCtD
Ponatinib—SRC—endothelium—malignant glioma	0.00141	0.0179	CbGeAlD
Ponatinib—FGFR3—embryo—malignant glioma	0.00139	0.0176	CbGeAlD
Ponatinib—SRC—blood vessel—malignant glioma	0.0013	0.0165	CbGeAlD
Ponatinib—KDR—endothelium—malignant glioma	0.00129	0.0164	CbGeAlD
Ponatinib—Febrile neutropenia—Carmustine—malignant glioma	0.00125	0.016	CcSEcCtD
Ponatinib—Febrile neutropenia—Temozolomide—malignant glioma	0.0012	0.0154	CcSEcCtD
Ponatinib—KDR—blood vessel—malignant glioma	0.00119	0.0151	CbGeAlD
Ponatinib—Deep vein thrombosis—Temozolomide—malignant glioma	0.00119	0.0153	CcSEcCtD
Ponatinib—KIT—endothelium—malignant glioma	0.00115	0.0146	CbGeAlD
Ponatinib—FGFR3—telencephalon—malignant glioma	0.00113	0.0143	CbGeAlD
Ponatinib—Imatinib—NTRK1—malignant glioma	0.00111	0.22	CrCbGaD
Ponatinib—Nilotinib—PDGFRA—malignant glioma	0.0011	0.219	CrCbGaD
Ponatinib—KIT—blood vessel—malignant glioma	0.00106	0.0134	CbGeAlD
Ponatinib—Nilotinib—BRAF—malignant glioma	0.00101	0.2	CrCbGaD
Ponatinib—BCR—telencephalon—malignant glioma	0.000976	0.0124	CbGeAlD
Ponatinib—Hepatotoxicity—Carmustine—malignant glioma	0.000971	0.0124	CcSEcCtD
Ponatinib—RET—embryo—malignant glioma	0.000956	0.0121	CbGeAlD
Ponatinib—FGFR4—central nervous system—malignant glioma	0.00094	0.0119	CbGeAlD
Ponatinib—Hepatotoxicity—Temozolomide—malignant glioma	0.000938	0.012	CcSEcCtD
Ponatinib—Hyperaesthesia—Temozolomide—malignant glioma	0.000923	0.0118	CcSEcCtD
Ponatinib—FGFR4—cerebellum—malignant glioma	0.000919	0.0117	CbGeAlD
Ponatinib—Imatinib—PDGFRA—malignant glioma	0.000917	0.182	CrCbGaD
Ponatinib—FGFR2—embryo—malignant glioma	0.000908	0.0115	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—malignant glioma	0.000887	0.0113	CbGeAlD
Ponatinib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000881	0.0113	CcSEcCtD
Ponatinib—Petechiae—Temozolomide—malignant glioma	0.000881	0.0113	CcSEcCtD
Ponatinib—TEK—embryo—malignant glioma	0.000871	0.0111	CbGeAlD
Ponatinib—FGFR1—telencephalon—malignant glioma	0.000869	0.011	CbGeAlD
Ponatinib—FGFR2—brainstem—malignant glioma	0.000832	0.0106	CbGeAlD
Ponatinib—FGFR3—midbrain—malignant glioma	0.00081	0.0103	CbGeAlD
Ponatinib—FGFR3—spinal cord—malignant glioma	0.000791	0.01	CbGeAlD
Ponatinib—PDGFRA—embryo—malignant glioma	0.000789	0.01	CbGeAlD
Ponatinib—SRC—embryo—malignant glioma	0.000774	0.00982	CbGeAlD
Ponatinib—BCR—medulla oblongata—malignant glioma	0.000767	0.00974	CbGeAlD
Ponatinib—Neck pain—Carmustine—malignant glioma	0.000759	0.00973	CcSEcCtD
Ponatinib—Pulmonary embolism—Carmustine—malignant glioma	0.00075	0.00961	CcSEcCtD
Ponatinib—FGFR4—brain—malignant glioma	0.000746	0.00947	CbGeAlD
Ponatinib—FGFR2—telencephalon—malignant glioma	0.000739	0.00938	CbGeAlD
Ponatinib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000733	0.0094	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000725	0.00929	CcSEcCtD
Ponatinib—Pulmonary embolism—Temozolomide—malignant glioma	0.000725	0.00929	CcSEcCtD
Ponatinib—Skin exfoliation—Carmustine—malignant glioma	0.000716	0.00917	CcSEcCtD
Ponatinib—KDR—embryo—malignant glioma	0.000712	0.00904	CbGeAlD
Ponatinib—TEK—telencephalon—malignant glioma	0.000708	0.00899	CbGeAlD
Ponatinib—Neuropathy—Carmustine—malignant glioma	0.000704	0.00902	CcSEcCtD
Ponatinib—Influenza like illness—Temozolomide—malignant glioma	0.000704	0.00902	CcSEcCtD
Ponatinib—BCR—midbrain—malignant glioma	0.000701	0.0089	CbGeAlD
Ponatinib—Skin exfoliation—Temozolomide—malignant glioma	0.000692	0.00887	CcSEcCtD
Ponatinib—BCR—spinal cord—malignant glioma	0.000684	0.00869	CbGeAlD
Ponatinib—SRC—retina—malignant glioma	0.000684	0.00868	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—malignant glioma	0.000682	0.00867	CbGeAlD
Ponatinib—Neuropathy—Temozolomide—malignant glioma	0.00068	0.00872	CcSEcCtD
Ponatinib—Dry eye—Temozolomide—malignant glioma	0.000669	0.00858	CcSEcCtD
Ponatinib—Sepsis—Carmustine—malignant glioma	0.000651	0.00834	CcSEcCtD
Ponatinib—LYN—central nervous system—malignant glioma	0.000645	0.00819	CbGeAlD
Ponatinib—PDGFRA—telencephalon—malignant glioma	0.000641	0.00815	CbGeAlD
Ponatinib—FGFR3—central nervous system—malignant glioma	0.000641	0.00814	CbGeAlD
Ponatinib—KIT—embryo—malignant glioma	0.000631	0.00801	CbGeAlD
Ponatinib—KDR—retina—malignant glioma	0.000629	0.00799	CbGeAlD
Ponatinib—SRC—telencephalon—malignant glioma	0.000629	0.00799	CbGeAlD
Ponatinib—FGFR3—cerebellum—malignant glioma	0.000627	0.00796	CbGeAlD
Ponatinib—FGFR1—midbrain—malignant glioma	0.000624	0.00792	CbGeAlD
Ponatinib—RET—medulla oblongata—malignant glioma	0.000611	0.00776	CbGeAlD
Ponatinib—FGFR1—spinal cord—malignant glioma	0.000609	0.00773	CbGeAlD
Ponatinib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000605	0.00775	CcSEcCtD
Ponatinib—Nilotinib—CYP2B6—malignant glioma	0.000581	0.116	CrCbGaD
Ponatinib—KIT—brainstem—malignant glioma	0.000578	0.00734	CbGeAlD
Ponatinib—Hot flush—Temozolomide—malignant glioma	0.000562	0.00721	CcSEcCtD
Ponatinib—RET—midbrain—malignant glioma	0.000558	0.00709	CbGeAlD
Ponatinib—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000557	0.00714	CcSEcCtD
Ponatinib—Menopausal symptoms—Temozolomide—malignant glioma	0.000557	0.00714	CcSEcCtD
Ponatinib—TEK—medulla oblongata—malignant glioma	0.000556	0.00706	CbGeAlD
Ponatinib—BCR—central nervous system—malignant glioma	0.000555	0.00705	CbGeAlD
Ponatinib—ABL1—embryo—malignant glioma	0.000549	0.00697	CbGeAlD
Ponatinib—Hyponatraemia—Carmustine—malignant glioma	0.000547	0.007	CcSEcCtD
Ponatinib—RET—spinal cord—malignant glioma	0.000545	0.00692	CbGeAlD
Ponatinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000544	0.00698	CcSEcCtD
Ponatinib—BCR—cerebellum—malignant glioma	0.000542	0.00689	CbGeAlD
Ponatinib—FLT3—cerebellum—malignant glioma	0.000539	0.00684	CbGeAlD
Ponatinib—Face oedema—Carmustine—malignant glioma	0.000525	0.00673	CcSEcCtD
Ponatinib—FGFR2—spinal cord—malignant glioma	0.000517	0.00657	CbGeAlD
Ponatinib—KIT—telencephalon—malignant glioma	0.000513	0.00651	CbGeAlD
Ponatinib—LYN—brain—malignant glioma	0.000512	0.0065	CbGeAlD
Ponatinib—FGFR3—brain—malignant glioma	0.000509	0.00647	CbGeAlD
Ponatinib—TEK—midbrain—malignant glioma	0.000508	0.00646	CbGeAlD
Ponatinib—Face oedema—Temozolomide—malignant glioma	0.000508	0.00651	CcSEcCtD
Ponatinib—ABL1—brainstem—malignant glioma	0.000503	0.00639	CbGeAlD
Ponatinib—TEK—spinal cord—malignant glioma	0.000496	0.0063	CbGeAlD
Ponatinib—Hypokalaemia—Carmustine—malignant glioma	0.000495	0.00635	CcSEcCtD
Ponatinib—Dehydration—Temozolomide—malignant glioma	0.000489	0.00627	CcSEcCtD
Ponatinib—ABL1—retina—malignant glioma	0.000485	0.00616	CbGeAlD
Ponatinib—FGFR1—cerebellum—malignant glioma	0.000483	0.00613	CbGeAlD
Ponatinib—Dry skin—Temozolomide—malignant glioma	0.000482	0.00618	CcSEcCtD
Ponatinib—Hypokalaemia—Temozolomide—malignant glioma	0.000479	0.00613	CcSEcCtD
Ponatinib—Breast disorder—Temozolomide—malignant glioma	0.000475	0.00609	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000474	0.00607	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000464	0.00595	CcSEcCtD
Ponatinib—Abdominal distension—Temozolomide—malignant glioma	0.000458	0.00586	CcSEcCtD
Ponatinib—KDR—medulla oblongata—malignant glioma	0.000455	0.00577	CbGeAlD
Ponatinib—PDGFRA—spinal cord—malignant glioma	0.000449	0.00571	CbGeAlD
Ponatinib—Pancytopenia—Carmustine—malignant glioma	0.000447	0.00573	CcSEcCtD
Ponatinib—ABL1—telencephalon—malignant glioma	0.000446	0.00567	CbGeAlD
Ponatinib—RET—central nervous system—malignant glioma	0.000442	0.00561	CbGeAlD
Ponatinib—SRC—spinal cord—malignant glioma	0.000441	0.0056	CbGeAlD
Ponatinib—BCR—brain—malignant glioma	0.000441	0.00559	CbGeAlD
Ponatinib—Neutropenia—Carmustine—malignant glioma	0.00044	0.00564	CcSEcCtD
Ponatinib—RET—cerebellum—malignant glioma	0.000432	0.00548	CbGeAlD
Ponatinib—Pancytopenia—Temozolomide—malignant glioma	0.000432	0.00553	CcSEcCtD
Ponatinib—Neutropenia—Temozolomide—malignant glioma	0.000425	0.00545	CcSEcCtD
Ponatinib—Hyperglycaemia—Carmustine—malignant glioma	0.000424	0.00544	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000423	0.00541	CcSEcCtD
Ponatinib—Pneumonia—Carmustine—malignant glioma	0.000422	0.00541	CcSEcCtD
Ponatinib—FGFR2—central nervous system—malignant glioma	0.00042	0.00533	CbGeAlD
Ponatinib—Erectile dysfunction—Temozolomide—malignant glioma	0.000419	0.00537	CcSEcCtD
Ponatinib—KDR—midbrain—malignant glioma	0.000416	0.00528	CbGeAlD
Ponatinib—Weight decreased—Temozolomide—malignant glioma	0.000411	0.00527	CcSEcCtD
Ponatinib—Neuropathy peripheral—Carmustine—malignant glioma	0.000411	0.00527	CcSEcCtD
Ponatinib—FGFR2—cerebellum—malignant glioma	0.00041	0.00521	CbGeAlD
Ponatinib—Hyperglycaemia—Temozolomide—malignant glioma	0.00041	0.00526	CcSEcCtD
Ponatinib—Stomatitis—Carmustine—malignant glioma	0.000409	0.00524	CcSEcCtD
Ponatinib—Urinary tract infection—Carmustine—malignant glioma	0.000408	0.00522	CcSEcCtD
Ponatinib—Pneumonia—Temozolomide—malignant glioma	0.000408	0.00522	CcSEcCtD
Ponatinib—KDR—spinal cord—malignant glioma	0.000405	0.00515	CbGeAlD
Ponatinib—Infestation NOS—Temozolomide—malignant glioma	0.000405	0.00519	CcSEcCtD
Ponatinib—Infestation—Temozolomide—malignant glioma	0.000405	0.00519	CcSEcCtD
Ponatinib—KIT—medulla oblongata—malignant glioma	0.000403	0.00512	CbGeAlD
Ponatinib—TEK—central nervous system—malignant glioma	0.000402	0.00511	CbGeAlD
Ponatinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000397	0.00509	CcSEcCtD
Ponatinib—Stomatitis—Temozolomide—malignant glioma	0.000395	0.00506	CcSEcCtD
Ponatinib—Urinary tract infection—Temozolomide—malignant glioma	0.000394	0.00505	CcSEcCtD
Ponatinib—TEK—cerebellum—malignant glioma	0.000393	0.005	CbGeAlD
Ponatinib—FGFR1—brain—malignant glioma	0.000392	0.00498	CbGeAlD
Ponatinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000383	0.00491	CcSEcCtD
Ponatinib—Haemoglobin—Carmustine—malignant glioma	0.000378	0.00485	CcSEcCtD
Ponatinib—Haemorrhage—Carmustine—malignant glioma	0.000377	0.00483	CcSEcCtD
Ponatinib—Hypoaesthesia—Carmustine—malignant glioma	0.000375	0.0048	CcSEcCtD
Ponatinib—Oedema peripheral—Carmustine—malignant glioma	0.000371	0.00475	CcSEcCtD
Ponatinib—Connective tissue disorder—Carmustine—malignant glioma	0.00037	0.00474	CcSEcCtD
Ponatinib—KIT—midbrain—malignant glioma	0.000368	0.00468	CbGeAlD
Ponatinib—Haemoglobin—Temozolomide—malignant glioma	0.000366	0.00469	CcSEcCtD
Ponatinib—PDGFRA—central nervous system—malignant glioma	0.000365	0.00463	CbGeAlD
Ponatinib—Haemorrhage—Temozolomide—malignant glioma	0.000364	0.00466	CcSEcCtD
Ponatinib—Visual impairment—Carmustine—malignant glioma	0.000363	0.00465	CcSEcCtD
Ponatinib—Hypoaesthesia—Temozolomide—malignant glioma	0.000362	0.00464	CcSEcCtD
Ponatinib—KIT—spinal cord—malignant glioma	0.000359	0.00456	CbGeAlD
Ponatinib—Oedema peripheral—Temozolomide—malignant glioma	0.000358	0.00459	CcSEcCtD
Ponatinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000358	0.00458	CcSEcCtD
Ponatinib—SRC—central nervous system—malignant glioma	0.000358	0.00454	CbGeAlD
Ponatinib—PDGFRA—cerebellum—malignant glioma	0.000356	0.00453	CbGeAlD
Ponatinib—Eye disorder—Carmustine—malignant glioma	0.000352	0.00451	CcSEcCtD
Ponatinib—ABL1—medulla oblongata—malignant glioma	0.000351	0.00445	CbGeAlD
Ponatinib—RET—brain—malignant glioma	0.000351	0.00445	CbGeAlD
Ponatinib—Visual impairment—Temozolomide—malignant glioma	0.000351	0.00449	CcSEcCtD
Ponatinib—SRC—cerebellum—malignant glioma	0.000349	0.00444	CbGeAlD
Ponatinib—Flushing—Carmustine—malignant glioma	0.000349	0.00448	CcSEcCtD
Ponatinib—Eye disorder—Temozolomide—malignant glioma	0.00034	0.00436	CcSEcCtD
Ponatinib—Cardiac disorder—Temozolomide—malignant glioma	0.000338	0.00433	CcSEcCtD
Ponatinib—Flushing—Temozolomide—malignant glioma	0.000338	0.00433	CcSEcCtD
Ponatinib—Arrhythmia—Carmustine—malignant glioma	0.000336	0.00431	CcSEcCtD
Ponatinib—FGFR2—brain—malignant glioma	0.000333	0.00423	CbGeAlD
Ponatinib—Alopecia—Carmustine—malignant glioma	0.000333	0.00426	CcSEcCtD
Ponatinib—Angiopathy—Temozolomide—malignant glioma	0.00033	0.00423	CcSEcCtD
Ponatinib—Mental disorder—Carmustine—malignant glioma	0.00033	0.00423	CcSEcCtD
Ponatinib—KDR—central nervous system—malignant glioma	0.000329	0.00418	CbGeAlD
Ponatinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000328	0.0042	CcSEcCtD
Ponatinib—Malnutrition—Carmustine—malignant glioma	0.000328	0.0042	CcSEcCtD
Ponatinib—Erythema—Carmustine—malignant glioma	0.000328	0.0042	CcSEcCtD
Ponatinib—Chills—Temozolomide—malignant glioma	0.000327	0.00418	CcSEcCtD
Ponatinib—Alopecia—Temozolomide—malignant glioma	0.000322	0.00412	CcSEcCtD
Ponatinib—KDR—cerebellum—malignant glioma	0.000321	0.00408	CbGeAlD
Ponatinib—ABL1—midbrain—malignant glioma	0.000321	0.00407	CbGeAlD
Ponatinib—TEK—brain—malignant glioma	0.00032	0.00406	CbGeAlD
Ponatinib—Imatinib—PTGS1—malignant glioma	0.000319	0.0635	CrCbGaD
Ponatinib—Mental disorder—Temozolomide—malignant glioma	0.000319	0.00409	CcSEcCtD
Ponatinib—Back pain—Carmustine—malignant glioma	0.000317	0.00406	CcSEcCtD
Ponatinib—Erythema—Temozolomide—malignant glioma	0.000317	0.00406	CcSEcCtD
Ponatinib—Malnutrition—Temozolomide—malignant glioma	0.000317	0.00406	CcSEcCtD
Ponatinib—ABL1—spinal cord—malignant glioma	0.000313	0.00397	CbGeAlD
Ponatinib—Vision blurred—Carmustine—malignant glioma	0.000309	0.00396	CcSEcCtD
Ponatinib—Back pain—Temozolomide—malignant glioma	0.000306	0.00393	CcSEcCtD
Ponatinib—Anaemia—Carmustine—malignant glioma	0.000303	0.00388	CcSEcCtD
Ponatinib—Vision blurred—Temozolomide—malignant glioma	0.000299	0.00383	CcSEcCtD
Ponatinib—Leukopenia—Carmustine—malignant glioma	0.000293	0.00376	CcSEcCtD
Ponatinib—Anaemia—Temozolomide—malignant glioma	0.000293	0.00375	CcSEcCtD
Ponatinib—KIT—central nervous system—malignant glioma	0.000291	0.0037	CbGeAlD
Ponatinib—PDGFRA—brain—malignant glioma	0.000289	0.00368	CbGeAlD
Ponatinib—ABCB1—blood vessel—malignant glioma	0.000286	0.00363	CbGeAlD
Ponatinib—KIT—cerebellum—malignant glioma	0.000285	0.00362	CbGeAlD
Ponatinib—SRC—brain—malignant glioma	0.000284	0.0036	CbGeAlD
Ponatinib—Leukopenia—Temozolomide—malignant glioma	0.000284	0.00363	CcSEcCtD
Ponatinib—Hypertension—Carmustine—malignant glioma	0.000283	0.00363	CcSEcCtD
Ponatinib—ABCG2—telencephalon—malignant glioma	0.000282	0.00357	CbGeAlD
Ponatinib—Myalgia—Carmustine—malignant glioma	0.000279	0.00358	CcSEcCtD
Ponatinib—Cough—Temozolomide—malignant glioma	0.000276	0.00354	CcSEcCtD
Ponatinib—Hypertension—Temozolomide—malignant glioma	0.000274	0.0035	CcSEcCtD
Ponatinib—Myalgia—Temozolomide—malignant glioma	0.00027	0.00346	CcSEcCtD
Ponatinib—Arthralgia—Temozolomide—malignant glioma	0.00027	0.00346	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000268	0.00343	CcSEcCtD
Ponatinib—Oedema—Carmustine—malignant glioma	0.000268	0.00343	CcSEcCtD
Ponatinib—Infection—Carmustine—malignant glioma	0.000266	0.00341	CcSEcCtD
Ponatinib—Dry mouth—Temozolomide—malignant glioma	0.000264	0.00338	CcSEcCtD
Ponatinib—Thrombocytopenia—Carmustine—malignant glioma	0.000262	0.00336	CcSEcCtD
Ponatinib—KDR—brain—malignant glioma	0.000261	0.00332	CbGeAlD
Ponatinib—Oedema—Temozolomide—malignant glioma	0.000259	0.00331	CcSEcCtD
Ponatinib—Infection—Temozolomide—malignant glioma	0.000257	0.00329	CcSEcCtD
Ponatinib—ABL1—central nervous system—malignant glioma	0.000254	0.00322	CbGeAlD
Ponatinib—Nervous system disorder—Temozolomide—malignant glioma	0.000254	0.00325	CcSEcCtD
Ponatinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000253	0.00324	CcSEcCtD
Ponatinib—Skin disorder—Temozolomide—malignant glioma	0.000251	0.00322	CcSEcCtD
Ponatinib—Hyperhidrosis—Temozolomide—malignant glioma	0.00025	0.0032	CcSEcCtD
Ponatinib—ABL1—cerebellum—malignant glioma	0.000248	0.00315	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000244	0.00312	CcSEcCtD
Ponatinib—Insomnia—Carmustine—malignant glioma	0.000242	0.0031	CcSEcCtD
Ponatinib—Paraesthesia—Carmustine—malignant glioma	0.00024	0.00308	CcSEcCtD
Ponatinib—Dyspnoea—Carmustine—malignant glioma	0.000239	0.00306	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000236	0.00302	CcSEcCtD
Ponatinib—Insomnia—Temozolomide—malignant glioma	0.000234	0.003	CcSEcCtD
Ponatinib—Decreased appetite—Carmustine—malignant glioma	0.000233	0.00298	CcSEcCtD
Ponatinib—Paraesthesia—Temozolomide—malignant glioma	0.000232	0.00297	CcSEcCtD
Ponatinib—KIT—brain—malignant glioma	0.000231	0.00294	CbGeAlD
Ponatinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000231	0.00296	CcSEcCtD
Ponatinib—Dyspnoea—Temozolomide—malignant glioma	0.00023	0.00295	CcSEcCtD
Ponatinib—Constipation—Carmustine—malignant glioma	0.000229	0.00293	CcSEcCtD
Ponatinib—Pain—Carmustine—malignant glioma	0.000229	0.00293	CcSEcCtD
Ponatinib—Dyspepsia—Temozolomide—malignant glioma	0.000228	0.00292	CcSEcCtD
Ponatinib—Decreased appetite—Temozolomide—malignant glioma	0.000225	0.00288	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000223	0.00286	CcSEcCtD
Ponatinib—Fatigue—Temozolomide—malignant glioma	0.000223	0.00286	CcSEcCtD
Ponatinib—ABCG2—medulla oblongata—malignant glioma	0.000221	0.00281	CbGeAlD
Ponatinib—Pain—Temozolomide—malignant glioma	0.000221	0.00283	CcSEcCtD
Ponatinib—Constipation—Temozolomide—malignant glioma	0.000221	0.00283	CcSEcCtD
Ponatinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000219	0.0028	CcSEcCtD
Ponatinib—CYP2D6—brainstem—malignant glioma	0.000217	0.00276	CbGeAlD
Ponatinib—Body temperature increased—Carmustine—malignant glioma	0.000211	0.00271	CcSEcCtD
Ponatinib—Abdominal pain—Carmustine—malignant glioma	0.000211	0.00271	CcSEcCtD
Ponatinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000211	0.00271	CcSEcCtD
Ponatinib—Abdominal pain—Temozolomide—malignant glioma	0.000204	0.00262	CcSEcCtD
Ponatinib—Body temperature increased—Temozolomide—malignant glioma	0.000204	0.00262	CcSEcCtD
Ponatinib—ABCG2—midbrain—malignant glioma	0.000202	0.00257	CbGeAlD
Ponatinib—ABL1—brain—malignant glioma	0.000201	0.00256	CbGeAlD
Ponatinib—ABCG2—spinal cord—malignant glioma	0.000197	0.0025	CbGeAlD
Ponatinib—CYP2D6—telencephalon—malignant glioma	0.000193	0.00245	CbGeAlD
Ponatinib—Asthenia—Carmustine—malignant glioma	0.000192	0.00246	CcSEcCtD
Ponatinib—Asthenia—Temozolomide—malignant glioma	0.000185	0.00238	CcSEcCtD
Ponatinib—Diarrhoea—Carmustine—malignant glioma	0.000183	0.00235	CcSEcCtD
Ponatinib—Pruritus—Temozolomide—malignant glioma	0.000183	0.00234	CcSEcCtD
Ponatinib—Dizziness—Carmustine—malignant glioma	0.000177	0.00227	CcSEcCtD
Ponatinib—Diarrhoea—Temozolomide—malignant glioma	0.000177	0.00227	CcSEcCtD
Ponatinib—Dizziness—Temozolomide—malignant glioma	0.000171	0.00219	CcSEcCtD
Ponatinib—ABCB1—embryo—malignant glioma	0.000171	0.00217	CbGeAlD
Ponatinib—Vomiting—Carmustine—malignant glioma	0.00017	0.00218	CcSEcCtD
Ponatinib—Rash—Carmustine—malignant glioma	0.000169	0.00216	CcSEcCtD
Ponatinib—Dermatitis—Carmustine—malignant glioma	0.000169	0.00216	CcSEcCtD
Ponatinib—Headache—Carmustine—malignant glioma	0.000168	0.00215	CcSEcCtD
Ponatinib—Vomiting—Temozolomide—malignant glioma	0.000164	0.00211	CcSEcCtD
Ponatinib—Rash—Temozolomide—malignant glioma	0.000163	0.00209	CcSEcCtD
Ponatinib—Dermatitis—Temozolomide—malignant glioma	0.000163	0.00209	CcSEcCtD
Ponatinib—Headache—Temozolomide—malignant glioma	0.000162	0.00208	CcSEcCtD
Ponatinib—Nausea—Carmustine—malignant glioma	0.000159	0.00204	CcSEcCtD
Ponatinib—ABCG2—cerebellum—malignant glioma	0.000156	0.00199	CbGeAlD
Ponatinib—Nausea—Temozolomide—malignant glioma	0.000154	0.00197	CcSEcCtD
Ponatinib—ABCB1—retina—malignant glioma	0.000151	0.00192	CbGeAlD
Ponatinib—ABCB1—telencephalon—malignant glioma	0.000139	0.00176	CbGeAlD
Ponatinib—CYP2C8—brain—malignant glioma	0.000131	0.00166	CbGeAlD
Ponatinib—ABCG2—brain—malignant glioma	0.000127	0.00161	CbGeAlD
Ponatinib—CYP3A4—central nervous system—malignant glioma	0.000111	0.00142	CbGeAlD
Ponatinib—CYP2D6—central nervous system—malignant glioma	0.00011	0.00139	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—malignant glioma	0.000109	0.00139	CbGeAlD
Ponatinib—CYP2D6—cerebellum—malignant glioma	0.000107	0.00136	CbGeAlD
Ponatinib—ABCB1—midbrain—malignant glioma	9.97e-05	0.00127	CbGeAlD
Ponatinib—ABCB1—spinal cord—malignant glioma	9.73e-05	0.00124	CbGeAlD
Ponatinib—CYP2D6—brain—malignant glioma	8.71e-05	0.00111	CbGeAlD
Ponatinib—ABCB1—central nervous system—malignant glioma	7.89e-05	0.001	CbGeAlD
Ponatinib—ABCB1—cerebellum—malignant glioma	7.71e-05	0.000979	CbGeAlD
Ponatinib—ABCB1—brain—malignant glioma	6.26e-05	0.000795	CbGeAlD
Ponatinib—SRC—Signaling Pathways—HIF1A—malignant glioma	1.73e-06	8.98e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—malignant glioma	1.73e-06	8.97e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—malignant glioma	1.72e-06	8.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CD80—malignant glioma	1.72e-06	8.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APC—malignant glioma	1.72e-06	8.94e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CG—malignant glioma	1.72e-06	8.94e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—malignant glioma	1.72e-06	8.93e-06	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—malignant glioma	1.71e-06	8.9e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MDM2—malignant glioma	1.71e-06	8.9e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—malignant glioma	1.71e-06	8.87e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—RAF1—malignant glioma	1.7e-06	8.87e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—malignant glioma	1.7e-06	8.85e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGF—malignant glioma	1.7e-06	8.83e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—malignant glioma	1.69e-06	8.8e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTPN11—malignant glioma	1.69e-06	8.78e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—malignant glioma	1.69e-06	8.77e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—malignant glioma	1.68e-06	8.74e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—malignant glioma	1.68e-06	8.73e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—malignant glioma	1.68e-06	8.72e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—malignant glioma	1.67e-06	8.71e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—malignant glioma	1.67e-06	8.71e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—malignant glioma	1.67e-06	8.7e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—malignant glioma	1.67e-06	8.7e-06	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—malignant glioma	1.67e-06	8.7e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CAV1—malignant glioma	1.67e-06	8.68e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CB—malignant glioma	1.66e-06	8.66e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NCOR1—malignant glioma	1.66e-06	8.65e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—malignant glioma	1.66e-06	8.65e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—malignant glioma	1.66e-06	8.64e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—malignant glioma	1.66e-06	8.61e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KDR—malignant glioma	1.65e-06	8.59e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MDM2—malignant glioma	1.65e-06	8.59e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—malignant glioma	1.65e-06	8.58e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—malignant glioma	1.65e-06	8.57e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—malignant glioma	1.65e-06	8.56e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RAF1—malignant glioma	1.65e-06	8.56e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—malignant glioma	1.64e-06	8.53e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—malignant glioma	1.63e-06	8.46e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—malignant glioma	1.62e-06	8.45e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—malignant glioma	1.62e-06	8.4e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CB—malignant glioma	1.61e-06	8.35e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—F2—malignant glioma	1.59e-06	8.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FN1—malignant glioma	1.59e-06	8.27e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—malignant glioma	1.59e-06	8.27e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—malignant glioma	1.59e-06	8.25e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—malignant glioma	1.59e-06	8.24e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—malignant glioma	1.58e-06	8.23e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—malignant glioma	1.58e-06	8.2e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTP1—malignant glioma	1.58e-06	8.2e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—malignant glioma	1.57e-06	8.18e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—malignant glioma	1.57e-06	8.18e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT2—malignant glioma	1.57e-06	8.18e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BAD—malignant glioma	1.57e-06	8.17e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAV1—malignant glioma	1.57e-06	8.14e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—malignant glioma	1.56e-06	8.1e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOTCH1—malignant glioma	1.56e-06	8.09e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—malignant glioma	1.54e-06	8.03e-06	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—malignant glioma	1.54e-06	8.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—malignant glioma	1.53e-06	7.98e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—malignant glioma	1.53e-06	7.95e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CB—malignant glioma	1.53e-06	7.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CD80—malignant glioma	1.52e-06	7.93e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—malignant glioma	1.52e-06	7.91e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—malignant glioma	1.52e-06	7.91e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—malignant glioma	1.51e-06	7.88e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—malignant glioma	1.51e-06	7.87e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—malignant glioma	1.51e-06	7.87e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—malignant glioma	1.51e-06	7.86e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	1.51e-06	7.86e-06	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—malignant glioma	1.51e-06	7.85e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—malignant glioma	1.51e-06	7.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGF—malignant glioma	1.5e-06	7.82e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—malignant glioma	1.5e-06	7.81e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTPN11—malignant glioma	1.49e-06	7.77e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—malignant glioma	1.49e-06	7.73e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTP1—malignant glioma	1.49e-06	7.73e-06	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—malignant glioma	1.48e-06	7.71e-06	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—malignant glioma	1.48e-06	7.7e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—malignant glioma	1.48e-06	7.68e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—malignant glioma	1.48e-06	7.67e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—malignant glioma	1.46e-06	7.61e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—malignant glioma	1.45e-06	7.56e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NCOR1—malignant glioma	1.45e-06	7.54e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—malignant glioma	1.45e-06	7.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGF2—malignant glioma	1.45e-06	7.52e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—malignant glioma	1.44e-06	7.48e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—malignant glioma	1.43e-06	7.44e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—malignant glioma	1.43e-06	7.44e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—malignant glioma	1.43e-06	7.42e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—malignant glioma	1.42e-06	7.41e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—malignant glioma	1.42e-06	7.39e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—malignant glioma	1.42e-06	7.38e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—malignant glioma	1.41e-06	7.34e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—malignant glioma	1.41e-06	7.32e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—malignant glioma	1.41e-06	7.32e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—malignant glioma	1.41e-06	7.32e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—malignant glioma	1.41e-06	7.31e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—malignant glioma	1.4e-06	7.29e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—malignant glioma	1.4e-06	7.29e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—malignant glioma	1.4e-06	7.26e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—malignant glioma	1.39e-06	7.25e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—malignant glioma	1.39e-06	7.24e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT2—malignant glioma	1.39e-06	7.24e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—malignant glioma	1.39e-06	7.22e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—malignant glioma	1.38e-06	7.18e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—malignant glioma	1.38e-06	7.16e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—malignant glioma	1.38e-06	7.16e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—malignant glioma	1.37e-06	7.12e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NCOR1—malignant glioma	1.37e-06	7.1e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—malignant glioma	1.36e-06	7.05e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—malignant glioma	1.35e-06	7.04e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—malignant glioma	1.35e-06	7.03e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—malignant glioma	1.35e-06	7.03e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—malignant glioma	1.35e-06	7.02e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—malignant glioma	1.35e-06	7.01e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—malignant glioma	1.34e-06	6.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—malignant glioma	1.33e-06	6.94e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—malignant glioma	1.32e-06	6.87e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—malignant glioma	1.32e-06	6.85e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	1.32e-06	6.85e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.31e-06	6.83e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—malignant glioma	1.31e-06	6.82e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—malignant glioma	1.31e-06	6.8e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—malignant glioma	1.3e-06	6.76e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—malignant glioma	1.3e-06	6.75e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.3e-06	6.74e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—malignant glioma	1.3e-06	6.74e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—malignant glioma	1.29e-06	6.69e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—malignant glioma	1.28e-06	6.67e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF2—malignant glioma	1.28e-06	6.66e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—malignant glioma	1.28e-06	6.65e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—malignant glioma	1.28e-06	6.64e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—malignant glioma	1.27e-06	6.59e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—malignant glioma	1.27e-06	6.58e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—malignant glioma	1.25e-06	6.52e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—malignant glioma	1.25e-06	6.52e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—malignant glioma	1.25e-06	6.49e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—malignant glioma	1.24e-06	6.46e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—malignant glioma	1.24e-06	6.46e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—malignant glioma	1.24e-06	6.43e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—malignant glioma	1.24e-06	6.43e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—malignant glioma	1.24e-06	6.42e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—malignant glioma	1.23e-06	6.4e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—malignant glioma	1.22e-06	6.35e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—malignant glioma	1.21e-06	6.3e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—malignant glioma	1.21e-06	6.3e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—malignant glioma	1.21e-06	6.29e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—malignant glioma	1.21e-06	6.28e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.21e-06	6.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—malignant glioma	1.2e-06	6.23e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—malignant glioma	1.2e-06	6.22e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—malignant glioma	1.2e-06	6.22e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—malignant glioma	1.19e-06	6.21e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—malignant glioma	1.19e-06	6.21e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—malignant glioma	1.19e-06	6.2e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—malignant glioma	1.18e-06	6.14e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—malignant glioma	1.18e-06	6.14e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—malignant glioma	1.17e-06	6.1e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—malignant glioma	1.17e-06	6.08e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—malignant glioma	1.17e-06	6.06e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—malignant glioma	1.16e-06	6.01e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—malignant glioma	1.15e-06	6e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—malignant glioma	1.15e-06	5.98e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—malignant glioma	1.15e-06	5.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—malignant glioma	1.14e-06	5.95e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—malignant glioma	1.14e-06	5.92e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—malignant glioma	1.13e-06	5.9e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—malignant glioma	1.13e-06	5.87e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—malignant glioma	1.12e-06	5.83e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—malignant glioma	1.11e-06	5.79e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—malignant glioma	1.11e-06	5.79e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—malignant glioma	1.11e-06	5.77e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—malignant glioma	1.1e-06	5.74e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—malignant glioma	1.1e-06	5.72e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—malignant glioma	1.09e-06	5.68e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—malignant glioma	1.09e-06	5.65e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—malignant glioma	1.08e-06	5.63e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—malignant glioma	1.08e-06	5.6e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—malignant glioma	1.08e-06	5.6e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—malignant glioma	1.07e-06	5.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—malignant glioma	1.07e-06	5.58e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—malignant glioma	1.07e-06	5.57e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—malignant glioma	1.07e-06	5.54e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—malignant glioma	1.04e-06	5.4e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—malignant glioma	1.03e-06	5.34e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—malignant glioma	1.02e-06	5.29e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—malignant glioma	1.01e-06	5.28e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—malignant glioma	1.01e-06	5.27e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—malignant glioma	1.01e-06	5.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—malignant glioma	1.01e-06	5.27e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—malignant glioma	1.01e-06	5.24e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—malignant glioma	9.79e-07	5.09e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—malignant glioma	9.79e-07	5.09e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—malignant glioma	9.75e-07	5.07e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—malignant glioma	9.72e-07	5.05e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—malignant glioma	9.58e-07	4.98e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—malignant glioma	9.47e-07	4.93e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—malignant glioma	9.47e-07	4.92e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—malignant glioma	9.46e-07	4.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—malignant glioma	9.46e-07	4.92e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—malignant glioma	9.45e-07	4.92e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—malignant glioma	9.44e-07	4.91e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—malignant glioma	9.38e-07	4.88e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—malignant glioma	9.36e-07	4.87e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—malignant glioma	9.3e-07	4.84e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—malignant glioma	9.25e-07	4.81e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—malignant glioma	9.1e-07	4.73e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—malignant glioma	9.09e-07	4.73e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—malignant glioma	9.07e-07	4.72e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—malignant glioma	9.01e-07	4.68e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—malignant glioma	8.98e-07	4.67e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NCOR1—malignant glioma	8.93e-07	4.64e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—malignant glioma	8.92e-07	4.64e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—malignant glioma	8.74e-07	4.54e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—malignant glioma	8.37e-07	4.35e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—malignant glioma	8.29e-07	4.31e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—malignant glioma	8.25e-07	4.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—malignant glioma	8.19e-07	4.26e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—malignant glioma	8.18e-07	4.25e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—malignant glioma	8.17e-07	4.25e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	8.03e-07	4.17e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—malignant glioma	8e-07	4.16e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—malignant glioma	7.77e-07	4.04e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—malignant glioma	7.76e-07	4.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—malignant glioma	7.73e-07	4.02e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—malignant glioma	7.7e-07	4e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—malignant glioma	7.6e-07	3.95e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—malignant glioma	7.28e-07	3.79e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—malignant glioma	7.13e-07	3.71e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—malignant glioma	7.11e-07	3.7e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—malignant glioma	6.87e-07	3.57e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—malignant glioma	6.72e-07	3.49e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—malignant glioma	6.66e-07	3.46e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	6.63e-07	3.45e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—malignant glioma	6.56e-07	3.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—malignant glioma	6.4e-07	3.33e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	5.83e-07	3.03e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—malignant glioma	5.8e-07	3.02e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—malignant glioma	5.77e-07	3e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—malignant glioma	5.44e-07	2.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	5.08e-07	2.64e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—malignant glioma	5.03e-07	2.62e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—malignant glioma	5.03e-07	2.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—malignant glioma	4.74e-07	2.46e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—malignant glioma	4.71e-07	2.45e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—malignant glioma	4.39e-07	2.28e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—malignant glioma	4.11e-07	2.14e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—malignant glioma	3.87e-07	2.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	3.1e-07	1.61e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—malignant glioma	2.53e-07	1.32e-06	CbGpPWpGaD
